Mergers & Acquisitions ·
XpresTest repurchases all remaining shares for $2.7M to simplify capitalization ahead of sale
XWELXWELL, Inc.
On October 8, 2026, XpresTest, Inc., a subsidiary of XWELL, Inc., repurchased the final 279.5 outstanding shares of its common stock for an aggregate cash payment of approximately $2.7 million, or $9,634.09 per share. The transaction included the buyback of restricted stock awards held by Chairman Bruce T. Bernstein, CEO Ezra T. Ernst, and CFO Ian Brown, with all unvested shares becoming fully vested upon repurchase. This early completion simplifies XpresTest's capitalization in preparation for a previously announced sale to Express Wellness Group, LLC. The per-share price matches the valuation agreed upon by the buyer and XWELL under the Securities Purchase Agreement dated July 6, 2026. By paying these amounts upfront rather than treating them as sale expenses at closing, XWELL avoids dollar-for-dollar reductions in the purchase price payable by the Buyer. XWELL, Inc. operates in the healthcare diagnostics and wellness industry.